#Hutchmed

[trendstodaynet]

HUTCHMED to divest 45% stake in Shanghai Pharma (HCM:NASDAQ)

J Studios/DigitalVision via Getty Images HUTCHMED (China) Limited (NASDAQ: HCM) on Wednesday announced arrangements to divest 45% of its equity ownership in Shanghai Hutchison Pharmaceuticals Limited, its joint venture with Shanghai Pharmaceuticals Holding (OTCPK:SHPMF), for $608 million (RMB 4.5 billion) in cash . Hong Kong-based pharma said Chinese private

[newtras]

HUTCHMED to sell 45% stake in Shanghai Pharma (HCM:NASDAQ)

J Studios/DigitalVision via Getty Images HUTCHMED (China) Limited (NASDAQ:HCM) on Wednesday announced agreements to sell its 45% stake in Shanghai Hutchison Pharmaceuticals Limited, a joint venture with Shanghai Pharmaceuticals Holding (OTCPK:SHPMF), for $608 million (RMB 4.5 billion) in cash. The Hong Kong-based farm said the Chinese private Source link

[satrthere]

HUTCHMED to sell 45% stake in Shanghai Pharma (HCM:NASDAQ)

J Studios/DigitalVision via Getty Images HUTCHMED (China) Limited (NASDAQ:HCM) on Wednesday announced agreements to sell its 45% stake in Shanghai Hutchison Pharmaceuticals Limited, a joint venture with Shanghai Pharmaceuticals Holding (OTCPK:SHPMF), for $608 million (RMB 4.5 billion) in cash. The Hong Kong-based farm said the Chinese private Source link

[financepulse]

$HCM: Hutchmed China Ltd. sells 45% stake in a unit for $608M, expecting a $477M pre-tax gain. Funds to boost core businesses like cancer therapies.

[trinitydigest]

Marginal Zone Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys

http://dlvr.it/T854Lt

[columbianewsupdates]

Marginal Zone Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys

http://dlvr.it/T853nL

[thealphareporter]

Marginal Zone Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys

http://dlvr.it/T853J4

[newsheadlinesnow]

Marginal Zone Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys

http://dlvr.it/T84xks

[biotech-news-feed]

MAY 17, 2024 | 2:59 PM PDT | BIOCENTURY | MANAGEMENT TRACKSHUTCHMED NAMES NEW CHAIRMAN AS SIMON TO RETIRESBY Plus: Immunome promotes Max Rosett to CFO, and Mark de Jong becomes CTO at Full-Lifehttps://www.biocentury.com/article/652460/hutchmed-names #BioTech #science

[desmoinesnewsdesk]

Latest Developments in Follicular Lymphoma Treatment Pipeline 2023: FDA, EMA, and PMDA Approvals by AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma

http://dlvr.it/SzT5wP

[instadw]

Asia markets mixed; drugmaker Hutchmed debuts in Hong Kong

[marketstracker]

HCM – HUTCHMED (China) Limited

https://trendystocks.trade/hcm-hutchmed-china-limited/?utm_source=dlvr.it&utm_medium=tumblr

[techvercy]

SEC sets clock for delisting Chinese companies over US audit demand

SEC sets clock for delisting Chinese companies over US audit demand

Five Chinese companies listed in New York have been named by US regulators as the first of as many as 270 groups that will be delisted if they do not hand over detailed audit documents that back their financial statements. The US Securities and Exchange Commission said that fast-food giant Yum China, biotechnology groups BeiGene, Zai Lab and HutchMed, and technology company ACM Research faced…

[trinitydigest]

Latest Developments in Follicular Lymphoma Treatment Pipeline 2023: FDA, EMA, and PMDA Approvals by AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma

http://dlvr.it/SzT8TY

[columbianewsupdates]

Latest Developments in Follicular Lymphoma Treatment Pipeline 2023: FDA, EMA, and PMDA Approvals by AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharma

http://dlvr.it/SzT5DG